VM:CC - Voyageur Pharmaceuticals Ltd. Announces Private Placement

(TheNewswire)

Calgary, Canada – TheNewswire- January16, 2024 - Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) (USA:VYYRF) ("Voyageur" orthe "Company"), a provider of innovative medical imagingsolutions, is pleased to announce a proposed non-brokered privateplacement of up to 10,000,000 units ("Units") at a price of$0.08 per Unit, for gross proceeds of up to CND$800,000 (the"Offering"). Each Unit shall be comprised of one commonshare in the capital of the Company (each, a "CommonShare"). one Common Share purchase warrant (each, a"Warrant"), each Warrant exercisable at $0.15 fortwenty-four months from closing.

[ Voyageur maypay a cash commission or finder's fee to qualified non-related partiesof up to 8% of the gross proceeds of the Offering (up to $64,000) andissue broker warrants (the "Broker Warrants") equal to up to8% of the number of Units sold in the Offering (up to 800,000 BrokerWarrants). Each Broker Warrant will entitle the holder to acquire oneCommon Share at a price of $0.08 per Broker Warrant for a period ofone (1) year from the date of issuance .]

The gross proceeds received by Voyageur from theOffering will be used to advance Voyageur’s project in the followingorder:

Marketing and sales launch        $300,000

Product testing                        $100,000

Audit and listing / TSXV fees         $60,000

Corporate G&A                        $300,000

Commissions                        $40,000

Total $800,000

The Offering is being offered to all of the existingshareholders of Voyageur who are permitted to subscribe pursuant tothe Existing Shareholder Exemption. This offer is open until January31, 2024, or such other date or dates as the Company determines and one or more closings are expected tooccur, with the final closing anticipated for on or about February 8,2024.

Any existing shareholders interested in participatingin the Offering should contact the Company pursuant to the contactinformation set forth below.

The Company has set January 16, 2024, as the recorddate for determining existing shareholders entitled to subscribe forUnits pursuant to the Existing Shareholder Exemption. Subscriberspurchasing Units under the Existing Shareholder Exemption will need torepresent in writing that they meet certain requirements of theExisting Shareholder Exemption, including that they were, on or beforethe record date, a shareholder of the Company and still area shareholder as at theclosing date. The aggregate acquisition cost to a subscriber under theExisting Shareholder Exemption cannot exceed $15,000 unless thatsubscriber has obtained advice from a registered investment dealerregarding the suitability of the investment.

As the Company is also relying on the Exemption forSales to Purchasers Advised by Investment Dealers, it confirms thatthere is no material fact or material change related to the Companywhich has not been generally disclosed. In addition to offering theUnits pursuant to the Existing Shareholder Exemption and the Exemptionfor Sales to Purchasers Advised by Investment Dealers, the Units arealso being offered pursuant to other available prospectus exemptions,including sales to accredited investors. Unless the Company determinesto increase the gross proceeds of the Offering, if subscriptionsreceived for the Offering based on all available exemptions exceed themaximum Offering amount of CND$800,000, Units will be allocated prorata among all subscribers qualifying under all available exemptions.

Completion of the Offering is subject to regulatory approval including, but not limited to, theapproval of the TSX Venture Exchange. The Common Shares and Warrantsissued will be subject to a four month hold period from the date ofthe closing of the Offering. Insiders of the Company may participatein the Offering.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSX Venture Exchange, is in development of barium,iodine and carbon Active Pharmaceutical Ingredients (API) andhigh-performance, cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium, iodine andcarbon contrast imaging market, Voyageur aims tobecome a key player by producing its own barium, iodine, and fullereneminerals.

Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of its products byregulatory agencies worldwide. As the Company solidifies its presencein the market, it will transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.

Voyageur is committed to sustainability andenvironmental stewardship. The Company envisions a future where carbonneutrality is the norm, and to achieve this, it plans to buildstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, itaims to become 100% self-sufficient across all its manufacturingactivities. Voyageur's commitment to the environment sets it apart asa pioneer in the industry.

At the core of the Company's operations, Voyageur ownsa 100% interest in two barium sulphate (barite) projects, includingthe Frances Creek and Pedley Mountain properties. Additionally,Voyageur holds interests in a high-grade iodine, lithium, and brominebrine project situated in Utah, USA, further bolstering its positionin the industry. Voyageur also owns a 100% interest in two batterymineral projects which focus on copper/zinc development.

Voyageur's ambitious vision is to become the firstvertically integrated, carbon-neutral company in the imaging contrastmedia drug market. By controlling all primary input costs, from thesourcing of raw materials to final production, it plans to ensureunmatched quality and cost efficiency. Voyageur embodies the motto of" From the Earth to theBottle ," highlighting its commitment toresponsible sourcing and manufacturing practices.

For Further Information:

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

NOT FOR DISSEMINATION IN THE UNITEDSTATES

Cautionary Statement Regarding “Forward-Looking”Information

Copyright (c) 2024 TheNewswire - All rights reserved.